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 Passively Targeted Curcumin-Loaded PEGylated PLGA 
Nanocapsules for Colon Cancer Therapy In Vivo 
 Rebecca  Klippstein ,  Julie Tzu-Wen  Wang ,  Riham I.  El-Gogary ,  Jie  Bai , 
 Falisa  Mustafa ,  Noelia  Rubio ,  Sukhvinder  Bansal ,  Wafa T.  Al-Jamal , 
 and  Khuloud T.  Al-Jamal * 
 1.  Introduction 
 Nanotechnology-based drug delivery systems have the poten-
tial to enhance the effi cacy of poorly soluble drugs for sys-
DOI: 10.1002/smll.201403799
 Clinical applications of curcumin for the treatment of cancer and other chronic 
diseases have been mainly hindered by its short biological half-life and poor water 
solubility. Nanotechnology-based drug delivery systems have the potential to enhance 
the effi cacy of poorly soluble drugs for systemic delivery. This study proposes the 
use of poly(lactic-co-glycolic acid) (PLGA)-based polymeric oil-cored nanocapsules 
(NCs) for curcumin loading and delivery to colon cancer in mice after systemic 
injection. Formulations of different oil compositions are prepared and characterized 
for their curcumin loading, physico-chemical properties, and shelf-life stability. The 
results indicate that castor oil-cored PLGA-based NC achieves high drug loading 
effi ciency (≈18% w(drug)/w(polymer)%) compared to previously reported NCs. 
Curcumin-loaded NCs internalize more effi ciently in CT26 cells than the free drug, 
and exert therapeutic activity in vitro, leading to apoptosis and blocking the cell 
cycle. In addition, the formulated NC exhibits an extended blood circulation profi le 
compared to the non-PEGylated NC, and accumulates in the subcutaneous CT26-
tumors in mice, after systemic administration. The results are confi rmed by optical 
and single photon emission computed tomography/computed tomography (SPECT/
CT) imaging. In vivo growth delay studies are performed, and signifi cantly smaller 
tumor volumes are achieved compared to empty NC injected animals. This study 
shows the great potential of the formulated NC for treating colon cancer. 
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temic delivery. [ 1 ] These features have made biodegradable 
polymeric nanocpasules (NCs) one of the most widely used. 
They can achieve high water insoluble drug loading, facilitate 
small 2015, 11, No. 36, 4704–4722
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intratumoral distribution, and protect the active agent from 
premature degradation, allowing its sustained and controlled 
release. [ 2–4 ] NCs exhibit a typical core–shell structure in which 
active molecules are confi ned to an oil-core that is surrounded 
by a polymer membrane or coating. [ 5 ] Curcumin, has shown 
a wide range of pharmacological activities and has attracted 
great interest due to the possibility of tumor growth inhibition 
via multiple mechanisms. [ 6 ] Its anticancer potential is mediated 
through the inhibition and modulation of several intracellular 
signaling pathways leading to antitumor angiogenesis, [ 7 ] sup-
pression of proliferation, [ 8 ] and prevention of metastasis [ 9,10 ] 
as confi rmed in various in vitro and in vivo cancer studies. 
However, clinical applications of curcumin for the treatment 
of cancer and other chronic diseases have been hindered by its 
short biological half-life and poor aqueous solubility, resulting 
in poor bioavailability. [ 11 ] In vitro studies have established that 
curcumin-induced cancer cell death and promoted apoptosis at 
concentrations of 5 × 10 −6 –50 × 10 −6  m and after several hours 
of exposure. [ 6 ] In another study, patients with advanced colo-
rectal cancer were treated orally with curcumin at relatively 
high doses (3.6 g daily for four months); however, no partial 
responses to treatment were observed. [ 12 ] The development of 
an intravenous nanomedicine-based formulation of curcumin 
for the treatment of colon cancer is needed. Previous studies 
have shown that nanoparticles (NPs) have improved curcumin 
therapeutic effects when compared to free curcumin. [ 13,14 ] 
Few of these reports used PEGylated NPs and only one study 
reported curcumin formulation in PEGylated poly(lactic-co-
glycolic acid) (PLGA)-lecithin NP for the treatment of colon 
cancer. [ 15 ] To our knowledge, no studies so far have investi-
gated the therapeutic potential of curcumin NCs for the treat-
ment of colon cancer in vivo after systemic administration. 
 In this work, oil core NC of high curcumin loading and 
optimum physico-chemical properties and shelf-life stability 
was prepared. The cellular uptake and cytotoxicity profi le of 
PEGylated NCs were tested in CT26 cells in vitro. Organ bio-
distribution profi le was studied by optical and single photon 
emission computed tomography/computed tomography 
(SPECT/CT) imaging. Tumor uptake and therapeutic effi cacy 
were tested after multiple intravenous injections at 16 mg 
curcumin per kg dose in CT26 tumor bearing mice. 
 Overall, castor oil curcumin-loaded NC achieved ≈95% 
drug loading and exhibited sustained drug release profi le 
in presence or absence of serum. Effective cell killing and 
apoptosis were achieved in CT26 cells in vitro. PEGylated 
NC showed good tumor accumulation and prolonged blood 
circulation profi le facilitating enhanced permeation and 
retention (EPR) effect. In vivo therapeutic study suggests 
the promising potential of the reported delivery system for 
treating colon cancer using repetitive and high-dose therapy. 
 2.  Results 
 2.1.  Synthesis of PLGA Conjugates and Conﬁ rmation by FT-IR 
and  1 H NMR 
 In this study, we aimed at synthesizing long-circulating 
PEGylated PLGA conjugates which are capable of encapsu-
lating curcumin for subsequent cancer therapy in vivo. More-
over, the synthesis of radiolabeled conjugates was carried out 
in order to be able to track the NCs after systemic adminis-
tration in tumor bearing mice. The synthetic approaches 
are schematically presented in  Scheme  1 . This was based on 
reacting PLGA-COOH with excess PEG bis-amine to form 
PLGA–NH-PEG–NH 2 conjugate (conjugate  3 ). The excess 
of unreacted PEG bis-amine was removed by dialysis against 
deionized water while excess dicyclohexylcarbodiimide (DCC), 
 N -hydroxysuccinimide (NHS), and dicyclohexylurea (DCU) 
were removed by precipitation of the polymer in diethylether 
small 2015, 11, No. 36, 4704–4722
 Scheme 1.  Synthesis of the conjugates. Conjugate  3 (PLGA 18KDa -PEG 3.5KDa -NH 2 ) was used as a main polymer to formulate NC. Conjugate  6 (PLGA 18KDa -
PEG 3.5KDa -NH-DTPA) contained the chelating molecule DTPA to facilitate radiolabeling of the conjugate with radioisotopes.
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where the by-products remain soluble. Characterization of 
PLGA–NH-PEG–NH 2 (Conjugates  3 ) was performed by 
FT-IR and  1 H NMR (Figure S1, Supporting Information). 
 FT-IR chart (Figure S1C, inset, Supporting Information) 
confi rmed the conjugation of PEG to the activated PLGA-
COOH through the appearance of vibration frequencies at 
1621 cm −1 (amide C O) and 1563 cm −1 (N H bond) that 
were absent in PLGA-COOH (compound  1 ) and PEG bis-
amine (compound  2 ) charts (Figure S1A,B, Supporting Infor-
mation).  1 H NMR also confi rmed the presence of PLGA 
and PEG protons on the NMR spectra. Peaks at 1.6, 4.8, 
and 5.2 ppm in  1 H NMR were related to the CH 3 , CH, and 
CH 2 protons of PLGA, respectively. The peak at 3.6 ppm 
accounted for the CH 2 protons of PEG blocks (Figure S1C, 
Supporting Information). The presence of the free NH 2 
group in the synthesized polymer was confi rmed by Ninhy-
drin/Keiser test (data not shown). 
 In order to be able to track the NC in vivo by gamma 
scintigraphy, PLGA-NH-PEG-NH-DTPA was synthesized to 
be incorporated into the NC during the formulation process. 
A two-step reaction was followed; PEG bis-amine was fi rstly 
reacted with DTPA (4:1). H 2 N-PEG-NH-DTPA (conjugate 
 5 ) was purifi ed by elution through SP-Sephadex C25 column. 
The presence of monofunctionalized H 2 N-PEG-NH-DTPA 
was confi rmed by Ninhydrin test (data not shown). 
 Conjugation of DTPA to PEG bis-amine was confi rmed 
by FT-IR ( Figure  1 A) through the appearance of vibra-
tion frequencies at 1621 cm −1 (amide C O) and 1563 cm −1 
(N H bond) and the reduction in the amine bond vibra-
tion at 3400 nm indicating coupling of one of the amine 
terminals. Conjugate  5 was then reacted with the acti-
vated form of PLGA-COOH resulting in the formation of 
PLGA-HN-PEG-NH-DTPA (conjugate  6 ). Conjugate  6 
was characterized by FT-IR and  1 H NMR (Figure  1 B).  1 H 
NMR indicated the presence of PLGA protons (1.6, 4.8, and 
5.2 ppm) in addition to PEG protons (3.6 ppm). 
 2.2.  Quantiﬁ cation of PEG Contents in the Conjugates 
 For further characterization of the conjugates, the PEG con-
tent in conjugates  3 and  6 was measured with the BaCl 2 /I 2 col-
orimetric assay as described in SI. PEG content was found to 
be in the range of 14.8%–16% of the total polymer weight. This 
indicated that 89.4%–92.5% of PLGA polymer was conjugated 
to PEG. This proves the effi ciency of the applied methods in 
incorporating large amounts of PEG into the polymer. 
 2.3.  Formulation and Physico-Chemical Characterization of NCs 
 After synthesis and confi rmation of the structures of the 
conjugates, curcumin containing NCs were formulated using 
one of the following oils as a core material: (a) castor oil, 
small 2015, 11, No. 36, 4704–4722
 Figure 1.  Characterization of the conjugates by  1 H NMR and FT-IR.  1 H NMR spectra (CDCl 3 ) and FT-IR spectra (ATR mode) of A) conjugate  5 (NH 2 -
PEG 3.5KDa -NH-DTPA) and B) conjugates  6 (PLGA 18KDa -NH-PEG 3.5KDa -NH-DTPA).
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(b) soybean oil or (c) miglyol812 oil. All formulations were 
prepared using the nanoprecipitation method ( Scheme  2 ). 
Unencapsulated drug was removed by gel fi ltration using 
water. The purifi ed formulations were characterized for their 
hydrodynamic diameter, polydispersity index (PDI), and 
zeta potential immediately after purifi cation and over 28 d 
storage at 4 °C ( Table  1 ). The hydrodynamic diameter ranged 
between 150 and 235 nm. On day 0, NC-castor oil exhibited 
signifi cantly lower size (150.55 ± 4.73) compared to NC-soy-
bean oil (235.42 ± 9.61) and NC-miglyol812 oil (206.5 ± 5.37). 
The PDI was ≤0.2 for the castor oil formulation but not for 
NC-soybean oil and NC-miglyol812 which showed a PDI 
value of 0.29 ± 0.01 and 0.26 ± 0.08, respectively, indicating 
greater heterogeneity of the sample. 
 NC-castor oil was found to be stable over the 28 d period 
storage with no signifi cant changes in size, PDI or Zeta 
potential observed over time (Table  1 ). On the other hand, 
NC-soybean and NC-miglyol812 oil exhibited slight but sig-
nifi cant increase and reduction in size, respectively, over the 
28 d storage. No apparent change in color or phase separa-
tion was observed in any of the formulations. 
 The size and PDI of curcumin aggre-
gates formed by their nano-precipitation 
method without PEGylated PLGA were 
72.5 and 0.15, respectively. Micelles are 
expected to form due to solubilisation 
with lecithin and Tween 80. 
 2.4.  Curcumin Loading and Encapsulation 
Efﬁ ciency 
 Initial screening for curcumin's solubility 
in oils used was carried out. Curcumin 
exhibited highest solubility in castor oil 
(1.91 mg mL −1 ) followed by miglyol812 
(1.26 mg mL −1 ) and soybean oil 
(0.37 mg mL −1 ), at 37 °C. Drug encapsula-
tion effi ciency (EE%) and loading effi ciency (LE%) for the 
different formulations were quantifi ed by UV–vis spectros-
copy and are described in Table  1 . The highest and lowest 
EE% were achieved for NC-castor oil (≈92%) and NC-soy-
bean oil (≈68%), respectively. Interestingly, EE% values were 
in agreement with the drug solubility values obtained for the 
drug in the different oils. Altogether NC-castor oil appeared 
to have the smallest size and PDI in addition to highest EE% 
and optimal shelf-life stability. It was therefore decided that 
further studies will be carried out using this formulation, 
thereafter referred to as NC. Drug-free NC is referred to as 
empty NC in this paper. 
 2.5.  Drug Release Studies 
 The release of curcumin from the PEGylated NCs was studied 
up to 24 h in the presence or absence of serum ( Figure  2 ). Cur-
cumin dissolved in DMSO was dialyzed and used as the 100% 
release control. In case of curcumin/DMSO control, a burst 
effect was seen with 50% and 100% release achieved within 
small 2015, 11, No. 36, 4704–4722
 Table 1.  Shelf-life stability of oil-cored curcumin-loaded NCs prepared using different oil cores. 
Day Hydrodynamic diameter a),b) 
[nm]
PDI a),b) Zeta-potential b),c) 
[mV]
Encapsulation 
effi ciency b),d) (EE%)
Loading effi ciency b),e) 
(LE%)
NC-castor oil 0 150.5 ± 4.7 0.16 −37.2 92.3 ±1.6 18.4 + 0.3
7 140.1 ± 4.5 0.23 −38.2
14 156.2 ± 5.7 0.18 −37.3
28 142.5 ± 5.9 0.16 −38.6
NC-soybean oil 0 235.4 ± 9.6 0.29 −45.3 68.9 + 2.9 13.7 + 0.6
7 201.2 ± 1.3 0.23 −37.3
14 205.1 ± 8.6 031 −38.0
28 212.7 ± 2.8 0.29 −38.4
NC-miglyol 812 oil 0 206.5 ± 5.3 0.26 −32.8 88 ±0.4 17.7 ± 0.1
7 188.7 ± 7.0 0.29 −34.6
14 188.9 ± 11.4 0.17 −34.5
28 168.5 ± 3.2 0.16 −34.0
 a) Measured by dynamic light scattering;  b) xpressed as mean ± SD ( n = 3);  c) Surface charge measured by electrophoresis;  d) Calculated as percentage of initial drug added, determined by spectro-
photometry;  e) Calculated as mass of incorporated drug divided by the weight of polymer, determined by spectrophotometry. 
 Scheme 2.  Preparation of curcumin-loaded NC by nanoprecipitation method. Schematic 
representation of the formulation method of the oil-cored NC. The organic phase composed 
of polymer, oil, lipophilic surfactant, and the drug dissolved in a water-miscible solvent is 
added dropwise to an aqueous phase containing a hydrophilic surfactant. Formation of NC 
takes place by solvent diffusion and polymer precipitation. Finally, the solvent is removed 
forming NC aqueous dispersion. The average diameter of NC is 160 nm.
full papers
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the fi rst 30 min and 4 h, respectively. Presence of serum did 
not affect its release profi le. NC, on the other hand, showed a 
sustained drug release profi le over the entire study period. The 
presence of serum signifi cantly increased drug release at all 
time points. At 24 h, ≈66% and 80% of the drug was released 
from the NC in absence or presence of serum, respectively. 
 2.6.  Intracellular Uptake of NC in CT26 Cells In Vitro 
 The intracellular uptake of intrinsically fl uorescence cur-
cumin in CT26 cells was expressed as mean fl uorescence 
intensity (MFI) and measured with fl ow cytometry. CT26 cells 
were treated for 6 h with free curcumin or NC, at 20 × 10 −6  m 
or 40 × 10 −6 m . Cells treated with NC showed signifi cantly 
higher MFI values compared to cells treated with free drug 
( Figure  3 A). The uptake was also concentration dependent 
on both treatments. MFI values of 79.9 ± 4.46 and 200.20 ± 
26.7 were obtained for NC treatment at 20 × 10 −6 and 40 × 
10 −6  m , respectively. 
 To confi rm intracellular delivery of the NCs, CT26 cells 
were treated with free curcumin or NC (20 × 10 −6  m ) for 
6 h and analyzed with confocal laser scanning microscopy 
(CLSM). Nuclei were counterstained with DAPI (blue) and 
uptake of curcumin was confi rmed by the presence of green 
signals (Figure  3 B). Results have confi rmed the enhanced 
uptake of NCs in CT26 cells compared to free curcumin. Pre-
cipitates of the drug could sometimes be found in the case 
of the free drug. Microscopy and fl ow cytometry studies indi-
cated effective drug uptake has been achieved with NCs. 
 2.7.  Cytotoxicity and Apoptotic Activity in CT26 Cells In Vitro 
 The cytotoxic effect of NC was initially screened in CT26 cells 
in vitro. Light microscopy images showed dose-dependent 
morphological changes when cells were 
treated with NC for 48 h, where cells 
appeared more round and smaller in size 
( Figure  4 A). As expected, cells treated 
with empty NC, at concentrations equiv-
alent to that used in drug-loaded NC, 
showed normal cell morphology. 
 Cell viability was assessed with 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay at 
10 × 10 −6 –100 × 10 −6  m free drug or the 
NC. A dose-dependent reduction in cell 
viability was seen in both treatments, 
more signifi cantly at 72 h compared to 
24 h (Figure  4 B). Interestingly, despite 
no signifi cant differences in cell viability 
between the free drug and the NC at 
60 × 10 −6 and 100 × 10 −6  m at both time 
points tested, NC showed more signifi cant 
reduction in cell viability compared to the 
free drug at low concentrations (10 × 10 −6 
and 30 × 10 −6  m ) at 72 h. 
 Sub-G1 analysis (Figure  4 C) allows 
quantifi cation of hypodiploid cell percentage entering into 
the SubG1 phase. NC treatment resulted in a dose-dependent 
increase in the SubG1 cell population. Both assays therefore 
confi rmed the anticancer effect of curcumin in CT26 cells. 
 2.8.  Cell Cycle Distribution Analysis in CT26 Cells In Vitro 
 Cell cycle analysis was investigated at 24 and 48 h post-
treatment (from 1 × 10 −6 to 0 × 10 −6  m NC) using fl ow 
cytometry. A shift in cell cycle distribution was detected at 
48 h (Figure  4 D,E) while no changes could be seen at 24 h 
(Figure S2, Supporting Information). NC treatment led to 
a steady increase in cell cycle arrest in S/G2 phase, upon 
increasing drug concentrations. Untreated cells and cells 
treated with 40 × 10 −6  m NC showed ≈23.5% and ≈29.85% 
of cells in S/G2 phase, respectively. Additionally, untreated 
cells and cells treated with 40 × 10 −6  m NC showed ≈16% and 
≈19.3% of cells in G2 phase, respectively. 
 2.9.  Tumor Uptake and Organ Biodistribution Studies In Vivo 
and Ex Vivo After Systemic Administration of NC 
 In Vivo tumor accumulation of PEGylated NC was assessed 
using DiR-labeled NCs in colon cancer CT26 murine tumor 
models. Whole body imaging was carried out up to 24 h 
after injection followed by imaging of excised tissues. Tumor 
uptake of NCs was clearly observed in bi-focally implanted 
tumors when imaged from the dorsal view ( Figure  5 A). On 
the other hand, no fl uorescence signals were detected from 
naïve mice. The fl uorescence image of excised organs is 
shown in Figure  5 B where the highest fl uorescence inten-
sities were measured from the tumors compared to other 
organs. Fluorescence intensities from each organ were fur-
ther quantifi ed and the results are shown in Figure  5 C. 
small 2015, 11, No. 36, 4704–4722
 Figure 2.  Release profi le of curcumin from NC. NCs were dialyzed against 1% w/v Tween 80 
in phosphate buffered saline (PBS), pH 7.4, in the presence and absence of 50% fetal calf 
serum. Drug concentration in the dialyzate was assessed by measuring the absorbance at 
420 nm. A control experiment was set up concurrently in which the same amount of curcumin 
was dissolved in DMSO and dialyzed for comparison. NCs exhibited a sustained release 
pattern when compared to the free drug.
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Taking into account the weights of the samples, slightly higher 
fl uorescence signals per gram of tissue were calculated from 
lung than from tumors. Lower values were obtained from the 
rest of the tissues which was expected from the fl uorescence 
image shown in Figure  5 C. 
 To confi rm curcumin uptake by tumor cells, non-DiR 
labeled curcumin-loaded NC was i.v. injected, tumors were 
excised 24 h later and tissue homogenate was assessed for drug 
fl uorescence by fl ow cytometry (FL2) (Figure  5 D). Higher 
MFI was observed for tumor homogenate of NC treated mice 
(84.2 ± 4.5) compared to saline injected mice (75.01 ± 1.01, 
*  P < 0.05), indicating drug uptake by tumor cells. 
 2.10.  Radiolabeling Optimization of DTPA-NC Formulations 
 For labeling of NCs, PLGA-NH-PEG-NH-DTPA (conjugate 
 6 ) was synthesized and incorporated in NCs. DTPA-NCs 
were then chelated with  111 In. The latter was selected due 
to its high capacity to be rapidly caged by DTPA with high 
thermodynamic equilibrium constant [ 16 ] in addition to its rel-
atively long half-life (67.9 h), which allows imaging for up to 
24 h. The radiolabeling effi ciency (calculated as a percentage 
of  111 In added to the labeling mixture) was tested using 
TLC technique after chelation  111 In. Only [ 111 In]-EDTA or 
[ 111 In]-DTPA chelates migrated to the solvent front while 
the radiolabeled polymer remained at the application point. 
 In order to optimize the radiolabeling effi ciency, NCs 
were prepared at increasing amounts of PLGA-NH-PEG-
NH-DTPA (1% to 50% w/w) (Figure S3, Supporting Infor-
mation). We concluded that inclusion of at least 5% of 
PLGA-NH-PEG-NH-DTPA in the NC formulation is 
needed to achieve 100% radiolabeling. Therefore, all the for-
mulations prepared for subsequent studies were prepared 
at 5% w/w mass ratio. In order to exclude the possibility of 
nonspecifi c binding between  111 InCl 3 and the synthesized 
conjugate, NCs without DTPA were used as negative con-
trols where no radiolabeling could be achieved thus con-
fi rming the chelation of  111 In to DTPA molecules of the 
DTPA-NCs (Figure S3, Supporting Information). To elimi-
nate the acetate buffer salts used during radiolabeling (pH 
5.5), the NC suspension was desalted by passing it through 
PD10 size exclusion column and the NCs were resuspended 
in PBS prior injection to mice. The samples were concen-
trated to a fi nal polymer concentration of 200 mg NCs per 
mL using the membrane centrifugation method. The absence 
small 2015, 11, No. 36, 4704–4722
 Figure 3.  Intracellular uptake of NC in CT26 murine colon cancer cells in vitro. A) CT26 cells were incubated with either the free drug or the NC 
formulation for 6 h. Cellular uptake was assessed by measuring the mean fl uorescence intensity (MFI) using fl ow cytometry and FL-2 detector. 
Drug uptake was enhanced, in a dose-dependent uptake pattern, when encapsulated in the NC. B) Cellular uptake was assessed by confocal laser 
scanning microscopy after 6 and 24 h. Curcumin uptake was indicated by green fl uorescence inside the cells and nuclei were counterstained with 
DAPI. Values are expressed as mean ± SD ( n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way ANOVA test). Asterisks correspond to statistically 
signifi cant differences between a particular group and control, unless indicated otherwise.
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of [ 111 In]-EDTA in the injected material was confi rmed once 
again after sample concentration and prior injection into the 
animals ( Figure  6 A). No signifi cant changes in hydrodynamic 
diameter or zeta potential were observed compared to non-
DTPA NC (Table S1, Supporting Information). 
 2.11.  Stability of NCs Radiolabeling in the Presence of Serum 
 Stability studies were assessed by incubating the radiolabeled 
NCs in either human serum (50% fi nal concentration) or PBS 
at 37 °C for 24 h. The results shown in Figure  6 B demonstrated 
high stability of all radiolabeled NCs in either human serum or 
PBS as all the  111 In was still bound to the NCs, after 24 h incu-
bation. It was demonstrated that the radiolabeled NCs were 
stable in serum so further in vivo studies were warranted. 
 2.12.  SPECT/CT Imaging of Radiolabeled DTPA-NC In Vivo 
 In Vivo organ biodistribution of radiolabeled PEGylated-
NC is shown in  Figure  7 A. The formulated NC exhibited 
small 2015, 11, No. 36, 4704–4722
 Figure 4.  Cytotoxicity of NC in CT26 murine colon cancer cells in vitro and cell cycle distribution analysis. CT26 cells were incubated with NC for 
24–72 h at increasing drug concentrations (from 10 × 10 −6 to 100 × 10 −6  M ). A) Microscopic examination of CT26 cells after treatment with NC for 
24 or 48 h. Cell rounding and reduction in cell number was observed for cells treated with drug-loaded NC in a time- and dose-dependent manner 
(scale bar 150 µm). B) Cell viability expressed as a percentage of control untreated cells, determined by MTT assay, was reduced as a function 
of drug concentration at both 24 and 72 h ( n = 5). C) Percentage SubG1 cell population (apoptotic cells), determined using PI staining method, 
signifi cantly increased, compared to untreated cells, when treated with 40 × 10 −6 M for 48 h ( n = 3). D) Relative changes in the percentage of cell 
cycle phases following 48 h of NC treatments. A shift in cell cycle distribution from G1 to S phase occurred in a dose-dependent manner ( n = 3). 
Representative histograms showing the cell cycle distribution are shown in E). Values are expressed as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 
0.001 versus control (one-way ANOVA test).
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extended blood circulation profi le (Figure  7 A,C) when com-
pared to the non-PEGylated NC formulation, as the latter 
exhibited fast accumulation in the liver and spleen at 30 min 
(Figure S4, Supporting Information). Prolonged blood cir-
culation profi le of these NCs is shown by the brightness in 
the major blood vessels and the heart. Tumor accumulation 
becomes more intense at 4 h and lasts up to 24 h. Such results 
clearly confi rmed fundamental differences in the organ 
biodistribution profi le between the non-PEGylated and 
PEGylated NCs showing that the PEGylated NC reported in 
this study exhibit stealth characteristics, thus propose them as 
potential candidates to passively deliver drugs to the tumors. 
Overall, the results correlated well with optical imaging study 
(Figure  5 ). 
 2.13.  Quantitative Biodistribution Study of Radiolabeled-NC in 
Mice after Systemic Administration 
 For quantitative determination of the NCs biodistribution 
and estimation of their uptake in CT26-tumor bearing Balb/c 
mice, radiolabeled NCs were injected via mouse tail vein at 
a dose of 600 mg (polymer) per kg. Mice were sacrifi ced at 
predetermined time intervals (30 min, 4 and 24 h) and the % 
injected dose (% ID)/gram tissue and % ID/organ were cal-
culated and results were plotted in Figure  7 B and Figure S5, 
Supporting Information. Blood clearance profi les were 
obtained and DTPA-NC showed 43 ± 2.99, 22 ± 2.09, and 
7.7 ± 4.60% ID in the blood after 1, 4, and 24 h, respectively 
(Figure  7 C). Signifi cantly higher tumor uptake was achieved 
after 24 h (3.9 ± 0.22% ID/g) compared to 1 and 4 h. Highest 
% ID/g tissue was found in the liver, spleen and kidneys after 
24 h. Almost 40% of the injected dose was found in the urine 
after 24 h (Figure  7 D). 
 2.14.  Quantitative Biodistribution Study of Curcumin in Mice 
after Systemic Administration 
 Quantitative determination of curcumin biodistribution in 
CT26-tumor bearing Balb/c mice was performed using a high-
performance liquid chromatography fl uorescence detection 
(HPLC-FLd) analytical method. Mice were injected via tail 
vein at a dose of 16 mg curcumin per kg and sacrifi ced at pre-
determined time intervals (1, 4, and 24 h). The % ID/g tissue 
and % I.D/organ ( Figure  8 B and Figure S6C, Supporting 
Information) were calculated using curcumin standard curves 
(Figure S6AB, Supporting Information). Commercially avail-
able curcumin consists of curcumin, demetoxycurcumin, and 
di-demethoxycurcumin. [ 17 ] These are observed at retention 
times of 21.2, 21.8, and 22.5 min and a single peak at 11.6 min 
was observed for dansyl- l -phenyl-alanine (internal standard). 
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 Figure 5.  In vivo and ex vivo organ biodistribution of DiR-labeled NC in CT26 tumor bearing Balb/c mice after systemic administration. Mice were 
i.v. injected with PBS, NC-DiR or unlabeled NC. Dose injected was equivalent to 312.5 mg polymer per kg or 18.75 mg DiR per kg. A) Representative 
whole body in vivo images obtained at 1, 4, 8, and 24 h post-injection. B) Representative ex vivo images of excised organs at 24 h post-injection. 
C) Ex vivo quantifi cation of fl uorescence signals of DiR-labeled NCs per gram of excised organs and tumors at 24 h. All images were obtained by 
IVIS Lumina III at exposure time: 1 s; binning factor: 4; f number 2, fi eld of view: D-12.5 cm; λex: 680, 700, 720, 740, and 760; λem: 790 nm. Data 
were analyzed by Living Image 4.3.1 Service Pack 2 software. For the purpose of quantifi cation of curcumin in the tumor, mice were i.v. injected 
with curcumin-loaded non-DiR labeled NC (16 mg curcumin per kg). 24 h later, tumors were excised, homogenized, and uptake was quantifi ed 
by fl ow cytometry. D) Representative histograms and mean fl uorescence intensity (MFI). Values are presented as mean ± SD ( n = 3), *  P < 0.05 
(Student's t-test).
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 The highest amount of curcumin was found in the liver, 
spleen, and lung after 1 h of injection. The % ID/g of tissue 
in these organs were 1.00% ± 2.02%, 4.80% ± 6.50%, and 
34.37% ± 13.24%, respectively. Tumor accumulation was 
observed at 1 h (0.12% ± 0.31) of NC injection and was 
enhanced further at 24 h (0.77%. ± 0.24%) (Figure  8 B, 
inset). Representative HPLC-FLd chromatograms are 
shown in Figure  8 A. A reduction in curcumin peak area 
in the liver was observed overtime. In the case of tumor 
tissue, however, peak area appeared more pronounced 
after 24 h. 
 2.15.  Tumor Growth Delay Studies in CT26 Tumor-Bearing 
Balb/c Mice 
 The anticancer potential of long circulating PEGylated 
curcumin-loaded NC was determined in CT26 mouse 
tumor bearing model. Mice were given four doses of cur-
cumin-loaded NC (16 mg curcumin per kg) or the empty 
NC, on day 11, 15, 19, and 24. DOX (5 mg kg −1 ) was 
included as a clinically used anticancer agent. NC or DOX 
therapy resulted in signifi cantly smaller 
tumor volumes compared to saline or 
empty NC injections, on day 23 and 
25 ( p < 0.05) ( Figure  9 ). On day 25, tumor 
volumes in saline, empty NC, DOX, and 
NC groups were 626 ± 71.98, 668 ± 122, 
308 ± 64, and 355 ± 80, respectively. No 
signifi cant differences between DOX and 
NC therapy were observed. 
 2.16.  Organ Histological Examination and 
Terminal Deoxynucleotidyl Transferase 
dUTP Nick End Labeling (TUNEL) Assay 
on Tumor Tissue 
 Histological analysis was carried out on 
H&E stained paraffi n embedded tissue 
sections sampled after the treatment 
period (25 d). No signifi cant histological 
changes were observed in lung, kidney, 
liver, and spleen compared to untreated 
tissues ( Figure  10 A). Such results indi-
cated the biocompatibility of the NC in 
vivo under the conditions tested. Apop-
totic/necrotic areas were present in all 
tumors but larger apoptotic/necrotic 
areas were detected in NC treated tumors 
(Figure  10 B). TUNEL assay was carried 
out to detect apoptotic cells. Apoptotic 
cells appear green, while other nuclei 
were counterstained using DAPI (in 
blue). As expected, large apoptotic areas 
were found in NC treated tumors, and 
were frequently found at the tumor mass 
periphery (Figure  10 B). 
 3.  Discussion 
 Several preclinical and clinical studies suggest that cur-
cumin can supress cancer cell proliferation and promote cell 
death. [ 18–20 ] However, the major roadblocks in its clinical 
translation for cancer therapy are related to its poor water 
solubility, poor pharmacokinetics and limited bioavailability 
at the tumor site. In the current report, long-circulating cur-
cumin-loaded oil-cored polymeric NCs were designed and 
formulated with the purpose of delivering high doses of cur-
cumin to colon solid tumors, after systemic administration, 
for therapeutic applications in vivo. It was hypothesised that 
the inclusion of an oil core into the polymeric NC will offer 
superior drug loading compared to other nanoformulations, 
while polymer PEGylation can prolong the blood circula-
tion profi le, maximizing the enhanced permeation and reten-
tion in solid tumors so that the drug can reach the tumor at 
high concentrations. The biocompatibility of the constituting 
polymers allows for multiple injections for better therapeutic 
outcomes. 
 The novelty of the performed study lies in two aspects; 
the use of PLGA-based polymeric oil-cored nanocapsules 
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 Figure 6.  Radiolabeling of NC with  111 In and radiolabel stability in serum. A) TLC of the 
radiolabeled NC immediately after radiolabeling, after desalting using PD10 desalting 
column and after concentrating the sample and just prior injection. No free  111 In was 
detected in all the samples. B) TLC of radiolabeled NC after incubation with either mouse 
serum or PBS for 1 and 24 h at RT. No free  111 In was detected indicating serum stability of 
the radiolabeled NCs.
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for curcumin loading, and the application of this type of 
formulation for in vivo colon cancer therapy. In an attempt 
to formulate NCs of smallest size, narrow polydispersity 
index and highest drug loading, different oil core types 
were studied. It has been described in the literature that 
the oil viscosity and the oil surface tension are important 
parameters contributing to determining the NC and the 
drug entrapment. [ 21,22 ] Interestingly, in our study the oil core 
type did not only affect NCs size and PDI, but it also altered 
drug loading into the NC. The smallest hydrodynamic size 
and narrowest PDI were obtained with castor oil-cored NC 
(150 ± 4.73 nm). Castor oil is the most viscous and has the 
highest surface tension compared to soybean oil [ 23,24 ] and 
Miglyol812 oil. [ 21 ] The high drug loading obtained with castor 
oil-cored NC correlates well with the highest solubility of the 
curcumin in this oil. 
 It has been shown that curcumin targets multiple sign-
aling pathways inducing cell cycle arrest [ 25 ] and that the 
small 2015, 11, No. 36, 4704–4722
 Figure 7.  In vivo whole body 3D SPECT/CT imaging and biodistribution of NC- 111 In in CT26 tumor-bearing balb/c. Mice were i.v injected with NC- 111 In 
at a dose of 600 mg polymer per kg. Mice for SPECT/CT imaging with tumor inoculated at one side only while tumor inoculated bifocally for gamma 
scintigraphy studies. A) Whole body 3D SPECT/CT imaging at 0–30 min, 4 and 24 h post-injection with scanning time of 40–60 min each. Cross-
sections were from heart (H), liver (L), spleen (S), kidney (KI), and tumor (T) at equivalent time points. Tumor accumulation was observed at 4 h 
post-injection and was enhanced over time. B) Organ biodistribution profi le values were expressed as percentage injected dose per gram tissues 
(% ID/g) at 1, 4, and 24 h after injection of 600 mg PLGA-PEG/kg. Inset in A is showing the uptake in tumors. Blood clearance profi le is shown 
in C); excretion profi le at 24 h is shown in D). Signals were quantifi ed by gamma scintigraphy. Results are expressed as means ± SD ( n = 3–4). 
* P < 0.05, ** P < 0.01 (one-way ANOVA test).
full papers
www.MaterialsViews.com
4714 www.small-journal.com © 2015  The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
principal mode of cell death induced by curcumin is apop-
tosis. [ 26 ] Several in vitro investigations have shown that 
curcumin inhibits cancer cell proliferation but high concen-
trations are needed. [ 27,28 ] In our study, MTT assay showed 
similar cell viability profi le of curcumin-loaded NC to that of 
the free drug when tested in CT26 cells in vitro. This is in line 
with other curcumin nanoformulations, i.e., the cross-linked 
copolymer micellar aggregates, [ 29 ] and the self-assembled 
methoxy-poly(ethylene glycol) palmitate nanocarriers [ 30 ] 
where comparable cytotoxicity profi les were observed for the 
nanoformulations and the free curcumin, in non-colon cancer 
cell lines. 
 The in vitro therapeutic effi cacy was not surprising as 
release studies showed that ≈60% and ≈80% of curcumin 
were released from the NC after 24 h, in presence of PBS and 
serum, respectively. Higher drug release in presence of serum 
is attributed to adsorption of serum proteins on NC and the 
subsequent destabilization effect, which has been reported 
with other curcumin NPs formulations. [ 15,31,32 ] Interestingly, 
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 Figure 8.  Organ biodistribution of curcumin in vivo by HPLC-FLd. Mice were i.v injected with curcumin-loaded NCs at a dose of 16 mg kg −1 . 
A) Representative chromatograms of extracted curcumin from liver and tumor tissues after 1 and 24 h. Highlighted area shows curcumin peaks 
at retention times of 21.2, 21.8, and 22.5 min. B) Major organ biodistribution profi le values for curcumin extracted from liver, lung, tumor (inset), 
heart, kidneys, and spleen at 1, 4, and 24 h post-injection, expressed as percentage injected dose per gram tissues (% ID/g). Curcumin uptake in 
tumors was observed at 1 h post-injection and was enhanced after 24 h. Results are expressed as means ± SD ( n = 3).
 Figure 9.  CT26 tumor growth delay in Balb/c after multiple injections of 
curcumin-loaded NC via tail vein. Mice were inoculated subcutaneously 
with 1 × 10 6 CT26 cells. Animals were then randomly divided into four 
groups: Control (♦), empty NC (  ), curcumin-loaded NC (  ), and DOX 
(positive control) (). Mice were injected i.v. a total of 4 injections on day 
11, 15, 19, and 24 post-tumor inoculation, at drug dose of 16 mg kg −1 
curcumin (containing 250 mg polymer per kg) or 5 mg kg −1 DOX. Tumor 
size measurement was carried out three times a week. Data are given 
as mean value ± SEM ( n = 10). Signifi cant differences were examined 
using one-way ANOVA following by Tukey’s multiple comparison test. 
* p < 0.05.
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cell imaging studies showed an improvement in curcumin 
uptake by CT26 cells when encapsulated in NCs compared 
to the free drug, as shown by fl ow cytometry and CLSM. 
The enhanced uptake is in agreement with other studies 
reporting curcumin nanoformulations such as EudragitS100 
polymer, [ 33 ] monoolein lipids, [ 34 ] and chitosan particles, [ 35,36 ] 
designed for treatment of colon cancer in vitro. 
 Sub-G1 analysis method was used to quantify the per-
centage cell population undergoing late apoptosis or 
necrosis. A signifi cant increase in the subG1 cell population 
was observed in cells treated with 40 × 10 −6  m drug concen-
tration (as NC). No adverse effects resulted from exposure 
to empty NC (no drug). Interestingly, similar fi ndings were 
found by another group when testing free curcumin toxicity 
in colorectal cancer cells, using the same assay. [ 37 ] This was 
also in agreement with investigations utilizing the water-sol-
uble albumin–curcumin conjugate, tested in noncolon cancer 
cell lines, [ 38 ] and curcumin NPs exposed to neuroblastoma, [ 39 ] 
glioblastoma, [ 40 ] and human squamous cell carcinoma in 
vitro. [ 41 ] When examining cell cycle progression, previous 
studies have shown that free curcumin inhibits the prolif-
eration of cancer cell by blocking its G2/M phase. [ 42–44 ] The 
same effect was proven with curcumin PLGA nanoformula-
tions tested in breast cancer [ 31,45 ] and leukaemia cancer cell 
lines. [ 46 ] Similarly, in our study, a concentration-dependent 
increase in cell population undergoing S/G2 phases, leading 
to a blockage into the G2/M phase was observed in CT26 
cells. 
 Solid-cored polymeric nanoparticles including PLGA 
NPs, [ 13,31,47,48 ] amphiphilic methoxy poly(ethylene glycol)-
polycaprolactone NPs, [ 49 ] cationic poly(butyl) cyanoacrylate 
NPs, [ 50 ] have been reported to encapsulate curcumin for 
cancer therapy. In an attempt to improve curcumin loading 
into the nanocarriers, other studies attempted the formula-
tion of polymeric oil-cored nanocapsules made of polylactic 
acid (PLA) NCs [ 51 ] or poly(ε-caprolactone) (PCL) NCs. [ 52 ] 
To our knowledge this is the fi rst study reporting formula-
tion and optimization of PLGA oil-cored NCs for curcumin 
encapsulation. 
 Encouragingly, the formulated NC in this study pre-
sented higher curcumin loading than either the solid-cored 
PLGA NP [ 47 ] or the oil-cored NC made of non-PLGA poly-
mers. [ 51,52 ] Previously reported solid PLGA NPs showed cur-
cumin loading effi ciency (w(drug)/w(polymer)%) ranging 
between 5% [ 15,31,53–56 ] and 15%. [ 57,58 ] Similar values were 
obtained for oil-cored polymeric NCs (≈5%–8%). [ 51,52 ] 
Interestingly, higher drug loading effi ciency was achieved 
in our study (≈18%). Final solubility of curcumin in the NC 
aqueous dispersion obtained here was up to 1.4 mg mL −1 . 
This is a great advantage as the same curcumin dose can be 
systemically injected, at a reduced polymer dose, compared 
to other studies. [ 15,54,59 ] 
 The second novel aspect of this study, directly linked to 
the aim of formulating polymeric NC of high drug loading, is 
performing the in vivo effi cacy study in colon cancer model 
after i.v. injection. Higher drug loading is crucial as high 
curcumin dose is required to achieve a therapeutic effect in 
vivo. [ 60 ] Curcumin is a poorly water-soluble molecule (solu-
bility in water is <0.1 mg mL −1 ) [ 61 ] which makes its systemic 
administration not possible. 
 There are dozens of formulations including liposomal 
curcumin, [ 62,63 ] PLA NCs, [ 51 ] PCL) NCs, [ 52 ] PLGA solid 
NPs, [ 13,32,47,64 ] amphiphilic methoxy poly(ethylene glycol)-
polycaprolactone NPs, [ 49 ] cationic poly(butyl) cyanoacrylate 
NPs, [ 50,65 ] have confi rmed the anticancer activity of curcumin 
nanoformulations in non-colon cancer cells in vitro [ 13,32,63,65 ] 
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 Figure 10.  Histological examination of major organs and TUNEL staining 
of tumors after multiple administrations via tail vein. A) Haematoxylin 
and eosin (H&E) stained sections of kidney, liver, spleen, and lung 
in CT26 tumor-bearing Balb/c mice. Mice were injected i.v. a total of 
four injections on day 11, 15, 19, and 24 d post-tumor inoculation 
at drug dose of 16 mg curcumin per kg or with saline. No histological 
abnormalities were found in major organs. B) H&E and TUNEL stained 
tumor sections examined after multiple administrations of NC. Larger 
apoptotic (white arrows) and necrotic (black arrows) areas were detected 
in NC injected animals compared to control animals. TUNEL and DAPI 
were counterstained to identify apoptotic (green) cells from the total cell 
population (blue nuclei) in the bottom row. Scale bar 100 µm for H&E 
and 500 µm for TUNEL.
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or in vivo. [ 47,49–52,62,64 ] To our knowledge, only two studies 
explored the effi cacy of curcumin nanoformulations against 
colon cancer cells. The fi rst study tested curcumin-loaded 
solid-cored PLGA NPs in vitro in HT29 cells, [ 15 ] while 
the second proved that curcumin-loaded monomethoxy 
poly(ethylene glycol)-poly(3-caprolactone) micelles can 
delay growth of C-26 colon cancer in vivo at a dose of 25 mg 
kg −1 after ten injections. [ 66 ] Neither of the two formulations 
was based on oil-cored polymeric NCs. In our study a dose of 
16 mg kg −1 was administered four times to the mice. 
 A major advantage of this formulation is the improved 
shelf life stability [ 67 ] which is a problem encountered with 
nanoemulsions in spite of their high capacity to solubilize 
hydrophobic drugs. [ 68 ] The polymeric shell offers an addi-
tional protection mechanism for the therapeutic cargo, when 
compared to curcumin nanoemulsions where the polymeric 
shell is absent. [ 69 ] The stability provided by the polymeric shell 
and the ease of polymer's chemical modifi cation, including 
PEGylation makes this system suitable for prolonged blood 
circulation profi le thus maximising the enhanced permeation 
and retention in solid tumors. 
 The tumor growth delay observed when injecting the cur-
cumin-loaded NC but not the non-medicated NC (Figure  9 ), 
is an indirect evidence of curcumin access to tumor cells. 
 To confi rm the presence of curcumin in the tumor, a 
direct HPLC-FLd analytical method was used for curcumin 
quantifi cation in major organs after intravenous administra-
tion of NC. Results showed that curcumin was distributed 
throughout the body with highest levels observed in the lung, 
spleen, and liver at 1 h. The highest curcumin levels in lung at 
1 h can be explained by the fact that NC present in the blood 
stream, pass through the heart and circulate into the lungs. In 
this fi rst stage of fi ltration, larger NC could have been trapped 
in small pulmonary capillary beds following intravenous 
injection of NCs. [ 70,71 ] Lung levels were reduced over time. 
These results are in accordance with radiolabeled NCs bio-
distribution studies, where a higher lung accumulation, com-
pared to liver and spleen, was observed at 1 h. Highest level 
of the radiolabeled NCs was detected in the kidneys, prob-
ably due renal excretion of  111 In-labeled polymer. Spleen and 
liver accumulation can be related to phagocytic cell uptake 
by the mononuclear phagocyte system. [ 72 ] Interestingly, the 
increase in radiolabeled-NCs levels in these organs over time 
was accompanied by a reduction in curcumin levels in these 
organs over time. This suggests that the drug is being metabo-
lized into other forms or being excreted from the body. It is 
worth mentioning that the sensitivity of HPLC-FLd is limited 
compared to gamma counting so percentages detected by 
HPLC-FLd could be underestimated. As opposed to therapy 
experiments where multiple injections were performed, only 
a single injection was performed for HPLC-FLd analysis of 
organs. These results are in agreement with those described 
by Ravichandran [ 71 ] and Tsai et al. [ 73 ] where curcumin NPs 
showed preference to spleen and lung in rats, while the free 
curcumin showed liver and kidney accumulation, as deter-
mined by HPLC. Despite differences observed in the major 
organ biodistribution of curcumin and radiolabeled NCs in 
this study, tumor uptake of both the drug and the NC showed 
similar trends, with an increase in tumor accumulation from 
1h to 24 h. Percentages of the drug in the tumor, like in other 
organs, were smaller than those obtained for the radiolabeled 
NCs presumably for the same reasons described above. 
 Additionally, qualitative fl ow cytometry studies on tumor 
tissue homogenates after 24 h of curcumin NCs is a direct 
evidence that curcumin reached tumor cells, indicating the 
ability of the drug to internalize into the cancer cells after 
extravasation. The fl uorescence signals are not high due 
to the poor intrinsic fl uorescence signals exhibited by cur-
cumin (Figure  5 D). [ 74 ] Finally, the hydrophobic dye (DiR) 
was encapsulated in the oil core of the NCs to mimic the 
hydrophobic curcumin. We observed by optical whole-body 
imaging that DiR reached the tumors (Figure  5 ) in a time-
course, which correlates with SPECT/CT and biodistribution 
studies with gamma counting. This suggests that the DiR dye 
is stably encapsulated inside the NC. Altogether we hypoth-
esise that the hydrophobic curcumin was stably encapsulated 
in the NC under the in vivo condition tested thus its biodis-
tribution profi le, at least the majority of it, can be matched to 
that of the NC. 
 Multiple injections (≈4 doses over 23 d treatment period) 
were carried out in this study and resulted in a signifi cantly 
delayed tumor growth, comparable to that achieved with 
multiple injections of free doxorubicin. The dosage used for 
this study was 16 mg curcumin per kg which is in the range 
between 2.5 and 40 mg curcumin per kg used in the reports 
mentioned previously. [ 47,49,50,62,64 ] The therapeutic effi cacy we 
observed with curcumin NCs is in line with other curcumin 
formulations or studies done on noncolon cancer models, 
which achieved a reduction between two [ 47,49,50,64 ] and 
three [ 62 ] times in the tumor volume. To our knowledge, this is 
the fi rst attempt to deliver curcumin oil-cored NCs to colon 
solid tumors in vivo for therapeutic purposes. 
 4.  Conclusion 
 This is the fi rst report on formulating oil-cored PLGA-based 
polymeric NC encapsulating curcumin. The formulation was 
capable of (i) reaching CT26 solid tumors after i.v. injec-
tion, (ii) releasing the therapeutically active drug at tumor 
site; (iii) inducing apoptosis of proliferating tumor cells and 
(iv) delayed tumor growth in vivo while sparing healthy 
normal tissues. Herein, this data suggests that PEGylated 
NCs could be a promising curcumin carrier for colon cancer 
therapy but that high doses and repeated administrations 
may be the key to achieve an effective anticancer therapy. 
 5.  Experimental Section 
 Material and Reagents : Dicyclohexylcarbodiimide (DCC), 
 N -hydroxysuccinimide (NHS), anhydrous dimethylformamide 
(DMF), diethylenetriaminepentaacetic dianhydride (DTPA), 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide 
(DiR), 4′,6-diamidino-2-phenylindole (DAPI), dialysis tubing (MWCO 
2000 Da), SP-Sephadex C-25 resin, and dansyl- L -phenylalanine 
were purchased from Sigma (UK). Polyoxyethylene-bis-amine (PEG-
bis-amine,  M w ≈ 3500) was purchased from JENKEM USA. 75/25 
small 2015, 11, No. 36, 4704–4722
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DL-lactide/glycolide conjugate (PLGA-COOH,  M w ≈ 18000) was a gift 
from Purac Biomaterials. Curcumin was purchased from Santa Cruz 
Biotechnology (UK). Snake Skin dialysis tubing (MWCO 10 000 Da) 
was purchased from Thermo-fi sher (USA). Soybean lecithin (Epi-
kuron 140 V) was a kind gift from Cargill Pharmaceuticals. Medium-
chain triglyceride (Miglyol812) was a generous gift from Cremer 
Oleo GmbH & Co. KG (GE). Castor oil, soybean oil, Tween 80, meth-
ylene chloride, acetone, absolute ethanol, dimethylsulphoxide 
(DMSO), and diethyl ether (ultra-pure grades) were obtained from 
 Sigma-Aldrich (UK). RPMI-1640 media, fetal bovine serum (FBS), 
penicillin/streptomycin, trypsin/EDTA, and phosphate buffered 
saline (PBS) were obtained from Gibco, Invitrogen (UK). The radio-
activity tracer [ 111 In]Cl 3 was obtained from Convidien UK com-
mercial LTD (UK) as an aqueous solution and used without prior 
purifi cation. Thin layer chromatography (TLC) strips for radiolabe-
ling were purchased from Agilent Technologies UK Ltd (UK). Dea-
dEnd Fluorometric TUNEL system was obtained from Pomega (UK). 
BD fl ow cytometry tubes were purchased from VWR (UK). Vectash-
ield mounting media was from Vector Labs (UK); 16% formalde-
hyde, methanol-free, was from Thermo Scientifi c Pierce. Isofl urane 
(IsoFlo) for anaesthesia was purchased from Abbott Laboratories 
Ltd (UK). All reagents were used without further purifi cation. 
 Synthesis of the Conjugates : Conjugate  3 . PLGA–NH-PEG–NH 2 
conjugate  3 was prepared according to the method developed 
by Yoo and Park, 2004 with some modifi cations. [ 18 ] Briefl y, PLGA-
COOH  1 (700 mg, 0.0412) together with a 4 molar excess of NHS 
(18.952 mg, 0.1648 mmol) and DCC (33.95 mg, 0.1648 mmol) 
were dissolved in anhydrous methylene chloride as presented in 
Scheme  1 . The reaction mixture was stirred under nitrogen atmos-
phere for 24 h at RT for activation of carboxylic group of PLGA-
COOH  1 . The resultant solution was fi ltered and added dropwise to 
a mixture of excess of PEG bis-amine  2 (721 mg, 0.206) and trieth-
ylamine (57.2 µL, 0.412 mmol) in anhydrous methylene chloride. 
PLGA-COOH: H 2 N-PEG-NH 2 stoichiometric molar ratio was 1:5. The 
reaction mixture was stirred under nitrogen atmosphere for 24 h at 
room temperature (RT). The resultant solution was precipitated by 
the addition of ice-cold diethyl ether to remove dicyclohexylurea 
by-product, unreacted NHS and DCC. The precipitated product, 
PLGA–NH-PEG–NH 2 3 was dried, dissolved in DMSO and dialyzed 
against deionized water for 2 d to remove excess unreacted PEG. 
Conjugate  3 was then lyophilized and stored at −20 °C till further 
use. PEG content was assessed colorimetrically upon reaction 
with barium chloride (in 1 N hydrochloric acid)/iodine solution as 
described in more details in the Supporting Information. 
 1 H NMR (400 MHz, CDCl 3 ): δ = 5.05−5.2 ( m , CH 2 PLGA), 4.75–
4.85 ( m, CH PLGA), 3.5–3.6 ( m , CH 2 PEG), 1.42–1.6 ( m , CH 3 PLGA). 
 Conjugate  5 . PEG-bis amine  2 (347.4 mg, 0.102 mmol) and 
triethylamine (1.39 µL, 10.3 mmol) were dissolved in dichlo-
romethane (20 mL). A solution of DTPA dianhydride  4 (9.11 mg, 
0.026 mmol) was dissolved in dichloromethane (10 mL) and was 
added to the reaction mixture in a dropwise manner at 0 °C. After 
addition was complete, the solution was stirred for 2 h. After this 
period of time, the solvent was evaporated under reduced pressure 
and the solid obtained was dissolved in chloroform and precipi-
tated in diethylether to remove unreacted DTPA. The obtained solid 
was subsequently dissolved in sodium acetate buffer (0.1  M , pH 
4.6) and loaded onto a SP-Sephadex C25 cation-exchanger column 
and eluted using sodium acetate buffer affording DTPA-PEG-amine 
product (conjugate  5 ). The product was monitored using Ninhydrin 
staining. The solution was dialyzed (MWCO 2000 Da) against 
deionized water and lyophilized. The as-obtained solid was dis-
solved in water and loaded onto a reverse phase C18 chromato-
graphic column in order to remove free DTPA. The separation was 
carried out using a gradient of the solvents water and acetone. The 
as-obtained polymer was lyophililized affording conjugate  5 as a 
white solid (295 mg, yield: 79%). The compound was stored as 
powder at −20 °C till further use. 
 1 H NMR (400 MHz, CDCl 3 ): δ = 7.6 ( bs , NH 2 PEG, 2H), 3.65 ( bs , 
320 H, CH 2 PEG), 3.42 ( s , CH 2 -COOH DTPA), 2.5–2.55 ( m , CH 2 -N 
DTPA). 
 Conjugate  6 . PLGA-COOH  1 (268 mg, 0.015 mmol) was dis-
solved in 10 mL of dichloromethane together with a 4 molar excess 
of NHS (9.2 mg, 0.06 mmol) and DCC (17.60 mg, 0.06 mmol). The 
reaction mixture was stirred under nitrogen atmosphere for 24 h at 
room temperature. After this period of time, the solution was fi l-
tered and the solvent was evaporated under reduced pressure. The 
obtained solid was dissolved in chloroform and precipitated by 
the addition of ice-cold diethyl ether to remove dicyclohexylurea 
by-product, unreacted DCC and NHS, affording activated PLGA 
polymer as a white solid (270 mg, yield: 99%). The obtained com-
pound (270 mg, 0.015 mmol) was dissolved in dichloromethane 
and added dropwise to a solution of conjugate  5 (295 mg, 
0.075 mmol) and triethylamine (28 µL, 0.23 mmol) in dichlo-
romethane. PLGA-COOH:H 2 N-PEG-NH-DTPA stoichiometric molar 
ratio used was 1:5. The reaction mixture was stirred under nitrogen 
atmosphere for 24 h at room temperature. After this period of 
time, the solvent was evaporated under reduced pressure and the 
product was dialyzed (MWCO 10 000 Da) against deionized water 
and lyophilized, affording conjugate  6 as a white solid (305 mg, 
yield: 93%). The compound was stored as powder at −20 °C till fur-
ther use. 
 1 H NMR (400 MHz, CDCl 3 ): δ = 5.0−5.2 ( m , CH 2 PLGA), 4.6–4.9 
( m , CH PLGA), 3.65 ( bs , 320 H, CH 2 PEG), 1.4–1.6 ( m , CH 3 PLGA). 
 Formulation of the NCs : Curcumin polymeric NCs were pre-
pared using the nanoprecipitation technique as described by Fessi 
et al. [ 75 ] and presented in Scheme  2 . Briefl y, polymer (25 mg), 
castor oil, Miglyol812 or soybean oil (300 µL), curcumin (5 mg), 
and soybean lecithin (25 mg) were dissolved in 5 mL of acetone/
ethanol (60:40 v/v) mixture. This organic phase was added drop-
wise into the aqueous phase (10 mL) containing Tween 80 (0.2%) 
as a hydrophilic surfactant; the mixture was maintained under 
magnetic stirring in the chemical hood for 30 min to allow solvent 
to diffuse and form NCs. Organic solvents were then eliminated 
by evaporation under reduced pressure using a Buchi rotavap. 
The fi nal volume of the colloidal suspension was adjusted to 
10 mL. 
 Solubility of Curcumin in Different Oils : The solubility of cur-
cumin in the different oils (castor oil, soybean oil, and miglyol812 
oil) used for NC preparation was determined by simple saturation 
shake-fl ask method. [ 76 ] Briefl y, excess amount of curcumin (4 mg) 
was placed in vials containing 1 mL of the oil, sealed and placed 
at 37 °C and shaken at 250 strokes min −1 for 48 h. Drug solubility 
was assessed by taking 100 µL of the supernatant and diluting in 
acetone and ethanol (ratio 3:2). The amount of curcumin dissolved 
in the organic solvent was determined using UV–vis spectropho-
tometer (Model UV-1601 PC; Shimadzu, Kyoto, Japan) by meas-
uring the absorbance at 418 nm and the amount of curcumin able 
to solubilize in the oil was calculated from relevant standard plots. 
small 2015, 11, No. 36, 4704–4722
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 Determination of Encapsulation Efﬁ ciency (EE%) : The encapsu-
lation effi ciency (EE%) of curcumin-loaded NCs was determined by 
measuring the amount of drug in the purifi ed and unpurifi ed nano-
capsules suspension. In order to purify the sample and remove 
the nonencapsulated free drug, NCs were passed through a PD10 
desalting column (GE Healthcare) and purifi ed fractions were col-
lected. To disrupt the NCs and quantify the total amount of drug in 
the purifi ed and unpurifi ed samples, 100 µL of the NCs prepara-
tions were diluted to 2 mL in ethanol and acetone (2:3 v/v). The 
amount of curcumin was determined using UV–vis spectrophotom-
eter (Model UV-1601 PC; Shimadzu, Kyoto, Japan) by measuring 
the absorbance at 418 nm. A standard plot of known curcumin 
concentrations was prepared using the organic phase of the nano-
capsules for each of the oil cores under identical conditions. The 
amount of curcumin in the measured samples was then calculated 
from the standard plots and the EE (%) was calculated using the 
following equation
 EE (%) (([Drug] total [Drug] free)/[Drug] total) 100.= − ×  
 Drug loading effi ciency (% LE) was calculated using the fol-
lowing equation
 
%LE Amount of curcuminencapsulated(mg)/(weight of polymer )
100
=
×  
 Size and Zeta Potential Measurements : Measurements of the 
average sizes and zeta potentials of the NCs were performed using 
dynamic light scattering (DLS) with a Nanosizer ZS Series (Malvern 
Instruments, Southborough, MA). Disposable polystyrene cells 
and disposable plain folded capillary Zeta cells were used. NC 
suspensions were diluted in deionized water and measurements 
were performed at 25 °C. Electrophoretic mobility was used to 
calculate the zeta-potential using the Helmholtz–Smoluchowski 
equation. The hydrodynamic size was presented as the average 
value for 20 runs, with triplicate measurements within each run. 
 Release Proﬁ le and Serum Stability In Vitro : Two millilitres of 
NC formulation containing 2.5 mg (curcumin) in 5 mL was taken 
and put into a 10 kDa dialysis bag. The dialysis membrane was 
dialyzed against 40 mL of 1% (w/v) Tween 80 in PBS, pH 7.4. 
Release was studied at 37 °C at 250 strokes min −1 . At predeter-
mined time points, 1.5 mL aliquots were taken and replaced by 
addition of an equal volume of the dialysate to maintain sink 
conditions. Drug concentration was assessed by measuring the 
absorbance at 420 nm using a Perkin–Elmer Lambda 35 UV–vis 
spectrophotometer, and calculated using a calibration curve 
for curcumin dissolved in the same media as the dialysate ( R 2 = 
0.993) over the range between 1 and 10 µg mL −1 ). A control experi-
ment was set up alongside in which the same amount of curcumin 
was dissolved in DMSO and dialyzed for comparison. This control 
was set up to eliminate nonspecifi c adsorption of the drug to the 
dialysis membrane. 
 Shelf Life Stability : NC suspensions were sealed in 7 mL glass 
vials and stored at 4 °C. The stability of NC dispersions were tested 
after 0, 7, 14, and 28 d of preparation by visual inspection of the 
physical properties (color and opacity) and also by size and zeta-
potential measurements. The measurements were done in tripli-
cate and presented as an average ± SD. 
 Cell Culture : The CT26 murine colon carcinoma (CT26; ATCC, 
CRL-2638) were cultured in Advanced RPMI media supplemented 
with 10% FBS, 50 U mL −1 penicillin, 50 µg mL −1 streptomycin, 
1%  L -glutamine, at 37 °C in 5% CO . Cells were routinely grown in 
75 cm 2 canted-neck tissue culture fl asks and passaged twice a 
week using Trypsin/EDTA at 80% confl uency. 
 Uptake Studies In Vitro by Flow Cytometry : Cells were seeded 
at a density of 5 × 10 4 in 24-well plates, allowed to attach over-
night and then treated with 20 × 10 −6 and 40 × 10 −6  M of cur-
cumin (free drug in DMSO or as NC). After treatment, the cells 
were washed twice with PBS, trypsinized and centrifuged at 
1500 rpm for 5 min and the cell pellet was resuspended in 250 µL 
of PBS. The internalization of curcumin or its NC was studied on 
10 000 gated cells by detecting curcumin's fl uorescence using 
FL2 channel detector and BD FACS Calibur fl ow cytometer (BD 
Biosciences). The measurements were done in triplicate and pre-
sented as mean ± SD. 
 Uptake Studies In Vitro by Confocal Laser Scanning Micros-
copy : CT26 cells were seeded onto glass coverslips at a density 
of 25 K cells per a well of a 24-well plates in RPMI media over-
night. Cells were then incubated with 0.5 mL of 20 × 10 −6  M NCs 
or free curcumin for 6 h. At the end of incubation period, cell 
were rinsed, fi xed (200 µL of 4% PFA for 15 min at RT) and sub-
sequently counterstained with DAPI. Coverslips were mounted on 
glass slides using VectaShield mounting media. Curcumin uptake 
was represented by the green signals, while nuclei were detected 
in blue. Confocal images were captured using a Nikon Eclipse Ti 
inverted microscope, Nikon, Tokyo, Japan, using an objective lens 
20×/0.75NA 505 nm output fi lter, and a Plan-Neofl uar 10 lens. 
 Cytotoxicity Studies In Vitro : CT26 cells were seeded in 96-well 
plates and incubated with different concentrations of curcumin or 
its NC (200 µL fi nal volume) in complete media for 24 and 72 h. 
Cytotoxicity was examined by MTT assay. Briefl y, at the end of the 
incubation period, media was removed and replaced with 120 µL 
of MTT solution at a fi nal concentration of 0.5 mg mL −1 . Cells were 
incubated for 3 h at 37 °C and 5% CO 2 . At the end of the incuba-
tion, formazan was dissolved in 200 µL of DMSO and the plate was 
read at 570 nm in a FLUO star OPTIMA plate reader (BMG Labtech) 
and the results were expressed as the percentage cell survival 
(mean ± SD) and calculated using the following equation: % Cell 
survival = (A570 nm of treated cells/A570 nm of untreated control 
cells) × 100. 
 Assessment of Late Apoptosis and Necrosis by Sub-G1 Quanti-
ﬁ cation : Late apoptosis and necrosis induced by curcumin-loaded 
NC were measured by quantifying the fraction of cells displaying 
reduced amount of DNA, named sub-G1 population. CT26 cells 
were seeded at 5 × 10 4 cells per well in 24-well plates and incu-
bated overnight at 37 °C with 5% CO 2 . Cells were then treated with 
20 × 10 −6 and 40 × 10 −6  M of NC. At the end of treatment period, 
fl oating cells were collected and adherent cells were trypsinized 
and transferred into BD fl ow cytometer tubes. After centrifugation 
at 800 × g for 5 min and washing in PBS, cells were resuspended 
in 100 µL of PBS and 900 µL of 70% cold ethanol for fi xation and 
stored overnight at 4 °C. Fixed cells were then centrifuged, washed 
in PBS, and treated in a mix of 250 µL of PBS and 250 µL of DNA 
extraction buffer (Na 2 HPO 4 190 × 10 
−3 M , Citric Acid 4 × 10 −3  M , 
pH 7.8) for 10 min at 37 °C. Samples were then centrifuged and 
resuspended in 50 µL of RNase in PBS (100 µg mL −1 ) before being 
stained for 30 min at 37 °C in the dark with 400 µL of propidium 
iodide (PI) solution (40 µg mL −1 of PI in PBS). Propidium iodide fl u-
orescence was analyzed by fl ow cytometry using a BD FACS Calibur 
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fl ow cytometer obtained from BD Bioscience (US). Finally, 10 
000 cells were gated and fl uorescence of Sub-G1 population was 
analyzed in triplicates for each condition using the FL2 detector. 
Results were expressed as average ± SD ( n = 3). 
 Cell Cycle Analysis by Flow Cytometry : To determine the per-
centage of cells that exist in specifi c phases of the cell cycle, fl ow 
cytometry analysis was performed. Briefl y, CT26 cells were seeded 
at a density of 5 × 10 4 in 24-well plates, allowed to attach over-
night and then treated with 1 × 10 −6 , 10 × 10 −6 , 20 × 10 −6 , and 
40 × 10 −6  M of NCs. Upon treatment, cells were washed with PBS, 
trypsinized and transferred into BD fl ow cytometer tubes. After 
centrifugation at 800 × g for 5 min and washing in PBS, cells were 
resuspended in 100 µL of PBS and 900 µL of 70% cold ethanol for 
fi xation for 1 h. Fixed cells were then centrifuged, washed in PBS, 
and treated with 50 µL of RNase in PBS (100 µg mL −1 ) before being 
stained for 30 min at 37 °C in the dark with 400 µL of propidium 
iodide (PI) solution (40 µg mL −1 of PI in PBS). Propidium iodide fl u-
orescence was analyzed by fl ow cytometry using a BD FACS Calibur 
fl ow cytometer obtained from BD Bioscience (US). Finally, 10 000 
cells were gated and fl uorescence was analyzed in triplicates for 
each condition using the FL2 detector and FlowJo software. Results 
were expressed as averages of percentage cell populations in each 
phase of the cell cycle ± SD ( n = 3). 
 Organ Biodistribution Studies In Vivo by Optical Imaging : All 
animal experiments were performed in compliance with the UK 
Home Offi ce (1989) Code of Practice for the housing and care of 
Animals used in Scientifi c Procedures. Female Balb/c mice (≈20 g) 
aged-4–6 weeks (Harlan) were inoculated subcutaneously with 
CT26 cells (1 × 10 6 cells in 0.1 mL PBS) at both lower fl anks. Mice 
( n = 3) were intravenously injected with prepared DiR-labeled NCs 
in PBS solution at a dose of 312.5 mg PLGA 18KDa -PEG 3.5KDa -NH 2 /
kg and 18.75 mg kg −1 DiR.and scanned at 1, 4, and 24 h post-
injection using an IVIS Lumina Series III In Vivo Imaging System 
(Caliper Life Sciences, Perkin Elmer, USA). Untreated animals were 
also included as controls. Animals were anesthetized with 1.5% 
isofl urane/98.5% oxygen to maintain sedation during the imaging 
procedure. Ex vivo imaging was carried out immediately after-
ward by imaging excised major organs (heart, lung, liver, spleen, 
and kidney) including tumors. Fluorescence images was obtained 
using DiR fi lter (680, 700, 720, 740, and 760/790 nm for excita-
tion/emission wavelengths) with exposure time of 1 s. All images 
were captured using a sequential acquisition spectra unmixing 
mode and were obtained using binning factor of 4, f number of 2, 
and fi eld of view of D-12.5 cm. The collected fl uorescence emis-
sion signals were stored in effi ciency units. 
 Radiolabeling of DTPA-Conjugates : In order to carry out the 
biodistribution studies, NCs were formulated using non-DTPA 
containing copolymers (conjugate  3 ) with increasing amount of 
conjugate  6 (PLGA-HN-PEG-NH-DTPA). Conjugate  6 was incorpo-
rated at 1%–50% in the formulation. NCs were then radiolabeled 
with Indium ( 111 In).  111 In was selected as the radioisotope for its 
capacity to rapidly be caged by DTPA with high thermodynamic 
equilibrium constant. [ 16 ] 111 In decays by electron capture with a 
physical half-life of 67.9 h, and others have previously shown that 
[ 111 In]DTPA complex exhibits a strong chelating effect in the pres-
ence of human serum. [ 77 ] The labeling with  111 InCl 3 was performed 
according to the method described before. [ 78 ] NCs were mixed 
(1:1(v/v)) with 0.2  M ammonium acetate buffer (pH 5.5) containing 
 111 InCl 3 for 30 min at room temperature. According to the sensi-
tivity of each study, the quantity of radioactivity was adjusted. 
After 30 min, the reaction was stopped by adding of 0.1  M EDTA 
solution to the mixture, to chelate the free  111 In. Unchelated  111 In 
was then removed using PD-10 desalting columns (GE Healthcare, 
UK) and the pH of the solution was adjusted to pH 7.0–7.4 at the 
same time due to the use of PBS as the equilibration buffer. Solu-
tions were later concentrated to the required volume for injection 
by centrifugal fi ltration (Amicon Ultra-4, Merck Millipore, UK) at 
4000 × g. 
 Efﬁ ciency and Stability of the Radiolabeling : Aliquots of the 
radioconjugates or [ 111 In]EDTA were diluted with PBS [1:5 (v/v)] 
and then spotted in glass microfi ber chromatography paper 
impregnated with silica gel . The strips were allowed to dry 
and developed with mobile phase of 50 × 10 −3  M EDTA in 0.1  M 
ammonium acetate. Strips were placed on a multipurpose storage 
phosphor screen (Cyclone, Packard, Japan) and kept in an auto-
radiography cassette (Kodak Biomax Cassette) for 15 min. Then, 
quantitative autoradiography counting was performed using a 
cyclone phosphor detector (Packard, Australia). The labeling sta-
bility was tested by incubation of the radioconjugates in the pres-
ence or absence of CD1 mouse serum. Aliquots were diluted in 
50% mouse serum or PBS [1:5 (v/v)], and incubated for 0 min, 
60 min and 24 h at RT. The percentage of [ 111 In]NC (immobile spot) 
or [ 111 In]EDTA (mobile spot) was evaluated by TLC, using the same 
protocol described above. 
 Tissue Biodistribution by Gamma Scintigraphy : CT26 tumor 
bearing Balb/c mice ( n = 3–4 per time point) were injected via 
the tail vein (i.v.) with 250 µL of the NCs dispersion at a dose of 
600 mg kg −1 polymer-[ 111 In]-labeled NC and 0.2–0.5 MBq of radio-
activity. At the end of each time-point, the animals were sacrifi ced 
and the major organs (brain, lung, liver, spleen, kidney, heart, 
stomach, intestine, muscle, skin, and bone (Femur)) were col-
lected, weighted, and placed in preweighted scintillation vials. 
Each organ was analyzed for [ 111 In] specifi c activity using an auto-
mated gamma counter (LKB Wallac 1282 Compugamma, Perki-
nElmer, UK) together with dilutions of injected dose with dead time 
limit below 60%. The gamma rays emitted by the radioisotope were 
detected, quantifi ed and corrected for physical radioisotope decay 
by the gamma counter. Radioactivity readings (counts per minute 
– CPM) were plotted as percentage of injected dose per organ 
or percentage of injected dose per gram of tissue. The data were 
expressed as the mean of triplicate or quadruplicate samples ± SD. 
 Tumor Uptake by Live Animal SPECT/CT Imaging in Tumor-
Bearing Mice : Anaesthetized CT26 tumor bearing Balb/c mice 
( n = 2) were injected intravenously with 250 µL of 600 mg kg −1 pol-
ymer-[ 111 In]-labeled NC and 10–12 MBq of radioactivity. Mice were 
imaged with nanoSPECT/CT scanner (Bioscan, USA) at different 
time points: immediately after the i.v. administration (0–30 min), 
after 3.5 and 24 h. For each mouse, a tomography was initially 
done (45 Kvp; 1000 ms) which allowed the calculation of certain 
parameters used in the SPECT and CT scanner, such as the starting 
line, fi nish line and axis of rotation of the acquisition, character-
istics of each mice. SPECT scans were obtained using a 4-head 
scanner with 1.4 mm pinhole collimators and the following set-
tings: number of projections: 24; time per projection: 60 s; dura-
tion of the scan 60 min. CT scans were obtained at the end of each 
SPECT acquisition using 45 Kvp. All data were reconstructed with 
MEDISO (medical Imaging System) and the fusion of SPECT and CT 
acquisitions were carried out using PMOD software. 
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 Curcumin Extraction from Tissue Samples and Analysis by 
HPLC-FLd : The extraction solvent was prepared from 98% acetoni-
trile and 2% TFA (v/v). For method validation, curcumin-loaded NCs 
were added to liver tissue at different concentrations from 0.25 to 
8.0 µg mL −1 . Spiked liver was transferred into 15 mL test tubes and 
vortex-mixed for 20 s. 1 mL of 1X PBS was added and samples were 
homogenized using an ULTRA-TURRAX T18 Homogenizer (IKA, GE). 
After the tissue was completely homogenized, 2 mL of the extraction 
solvent was added and were left under agitation overnight. Sam-
ples were then centrifuged at 3000× g for 5 min at 4 °C and 1 mL of 
the supernatant was transferred to a clean glass tube. The extrac-
tion was repeated twice with 1 mL of extraction solvent, and the 
pooled supernatants were concentrated using a centrifugal evap-
orator-Genevac EZ2 (Genevac Ltd, UK) at low heat setting (40 °C). 
The content was transferred to an injection sample vial, and 50 µL 
was injected into the HPLC-FLd system (Agilent Technologies) using 
a Phenomenex C18 column (150 × 2.1 mm, 3.6 µm) and a fl ow 
rate of 0.2 mL min. The mobile phase consisted of A: 0.1% TFA in 
H 2 O: acetonitrile (90:10) (v/v) and B: 0.1% TFA in H 2 O: acetonitrile 
(10:90) (v/v). The elution gradient was 10%–90% B in 30 min. 
Fluorescence detection, excitation 345 and emission 530 nm. 
 For HPLC-FLd analysis, working solutions of curcumin were 
prepared by dilution with the mobile phase to fi nal concentrations 
of 0.25, 0.5, 1.0, 2.0, 4.0, and 8.0 µg mL −1 , all containing dansyl-
 L -phenylalanine at 5 µg mL −1 , as an internal standard. The linearity 
of the detector responses for curcumin was determined for drug 
solutions and spiked tissues (liver), in duplicates, and the calibra-
tion curves were calculated by linear regression. The peak area 
ratio of curcumin to dansyl- L -phenylalanine was plotted against 
the concentration of curcumin. 
 Biodistribution Studies of Curcumin in Major Organs : Cur-
cumin-loaded NCs were administered by a single intravenous 
injection at a dose of 16 mg kg −1 into CT26 tumor bearing Balb/c 
mice and were sacrifi ced after 1, 4, and 24 h ( n = 3). Major organs 
(liver, lung, tumor, heart, kidney, and spleen) were removed and 
stored at −80 °C until curcumin was extracted as mentioned above 
for HPLC-FLd analysis. The amount of curcumin in the organs was 
determined in duplicates and a spiked tissue standard curve was 
included for each run. The data were expressed as the mean% 
ID/g of tissue ± SD. 
 Tumor Growth Delay In Vivo Studies : To determine the thera-
peutic action of NCs containing curcumin, tumor bearing Balb/c 
mice were randomly divided into four groups ( n = 10) and anes-
thetized using isofl urane and injected  via tail vein with (i) Saline; 
(ii) NC at 16 mg curcumin per kg in 200 µL; (iii) DOX at 5 mg kg −1 
in 200 µL (positive control) or (iv) empty NC, all prepared in PBS 
and injected every 4 d for a total of four doses. Mice were sacri-
fi ced by cervical dislocation when tumors reached 1000 mm 3 . Data 
are given as mean value ± SEM, with  n denoting the number of 
repeats. Signifi cant differences were examined using one-way 
ANOVA. Tukey's multiple comparison test was further employed 
after one-way ANOVA for the tumor growth delay study. A  p value of 
<0.05 was considered statistically signifi cant in all studies. 
 Histological Examination of Major Organs : For histological 
examination of organs, Balb/c female mice were injected via tail 
vein with 200 µL of NCs (16 mg curcumin per kg) dispersed in PBS 
and tissues of tumor, kidney, liver, and spleen were excised when 
tumor volume reached 1000 mm 3 . Organs were immediately fi xed 
in 10% neutral buffer formalin as 5 mm 2 pieces. Two pieces of each 
organ were then paraffi n-embedded and sectioned for haema-
toxylin and eosin stains (H&E) according to standard histological 
protocols at the Royal Veterinary College. All stained sections were 
analyzed using a Leica DM 1000 LED Microscope (Leica Microsys-
tems, UK) coupled with CDD digital camera (Qimaging, UK). 
 TUNEL Labeling Assay : For detection of apoptosis, the Dea-
dEnd Fluorometric TUNEL system was used to label nicked DNA 
through incorporation of fl uorescein-12-dUTP. Samples were incu-
bated with recombinant terminal deoxynucleotidyl transferase 
(rTdT) as per manufacturer’s instructions, and fl uorescein labeling 
was visualized using confocal laser mosaicing scanning micros-
copy (Nikon Eclipse Ti inverted microscope, Nikon, Tokyo, Japan) 
using an objective lens 20×/0.75NA 505-nm output fi lter, and a 
Plan-Neofl uar 10 lens. DAPI VectaShield was used to counterstain 
nuclei. Each image consists of 256 × 256 pixels and the fi nal 
mosaic consists of 12 × 15 images. 
 Tumor Uptake Quantitative Analysis of Systemically Administered 
NC by Flow Cytometry : For the quantifi cation of curcumin uptake in 
tumor tissue, Balb/c female mice were injected via tail vein with 
200 µL of NCs (16 mg curcumin per kg) dispersed in PBS. Tumor 
tissue processing was performed on ice and protected from light 
(whenever possible) in order to minimize the loss of viable cells and 
protect the fl uorescent drug. Tumors were disrupted in small pieces 
using scissors and a scalpel and were homogenized by adding the 
pieces into Trypsin-EDTA 0.5% for 30 min at 37 °C (vortexed every 
10 min) and passed through 10, 5, and 1 mL pipettes until pieces 
of tissue were no longer differentiated. Homogenates were further 
incubated in 5 mL of trypsin for 5 min at 37 °C. After, 20 mL of com-
plete RPMI were added and tumor homogenates were then strained 
through 70 µm strainers (BD Biosciences), in order to obtain 
uniform cell suspensions. Cells were then transferred to 15 mL 
polystyrene tubes and washed twice with ice-cold PBS. From this 
cell suspension, 1 × 10 6 cells were transferred to 5 mL polystyrene 
tubes and 50 000 cells were gated for the detection of curcumin 
using FL2 channel detector and BD FACS Calibur fl ow cytometer (BD 
Biosciences). The data were expressed as the mean ± SD. 
 Statistical Analysis : For all experiments, data were presented 
as mean ± SD except for therapy experiments; data were pre-
sented as mean ± SEM, where n denotes the number of repeats. 
Signifi cant differences were examined using one-way ANOVA.  p < 
0.05 was considered statistically signifi cant in all studies. 
 In case of therapy experiment, signifi cant differences were 
examined using one-way ANOVA following by Tukey’s multiple 
comparison test. *  p < 0.05. 
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 Supporting Information is available from the Wiley Online Library 
or from the author. 
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